Novartis (NVS) announced Friday positive topline results from a phase 3 study evaluating the efficacy and safety of Fabhalta in adult patients with paroxysmal nocturnal hemoglobinuria who were switched from other therapies.
The company said that after 24 weeks of treatment with twice-daily oral monotherapy of the drug, also called iptacopan, average hemoglobin levels improved compared with the baseline.
Paroxysmal nocturnal hemoglobinuria is a rare, chronic blood disorder that causes the production of red blood cells susceptible to premature destruction, leading to anemia, blood clots, and fatigue among other symptoms.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。